More Stories

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.

Cardiovascular Disease May 4, 2026

The True Cause of Sudden Cardiac Death May 4, 2026

It’s not often that a pair of studies completely challenges our assumptions in cardiology, but new data presented at HRS 2026 suggests myocardial infarction might not be […]

Cardiology April 30, 2026

Cardiac Wire’s Top Six of HRS 2026 April 30, 2026

The Heart Rhythm Society's Annual Meeting for 2026 electrified Chicago with talks of the latest EP tech, rhythm management debates, and insights into where remote patient monitoring is headed. Here are Cardiac Wire’s top-six takeaways from electrophysiology’s biggest weekend of the year.

Cardiology Testing April 27, 2026

Better hs-cTnT Assays, Lower Healthcare Burden April 27, 2026

Cardiac troponin assays might be the gold standard for diagnosing a heart attack in the ER, but a new JAMA study suggests the latest generation of tests could significantly reduce false positives and ultimately, health system burden.

Patient Engagement April 23, 2026

Calcium Supplements May Have CV Risks April 23, 2026

While the verdict is still out on whether or not calcium supplements support bone health, new research in JAHA suggests they’re not good for your heart.

Surgeries & Interventions April 20, 2026

A Look Into Real-World TTVR Results April 20, 2026

We’re finally starting to get some real-world data on treating tricuspid regurgitation with transcatheter tricuspid valve replacement (TTVR) and a new TVT registry study suggests TTVR outcomes are even better than previously thought.

Get twice-weekly insights on the biggest stories shaping cardiology.